Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Cost-effectiveness evaluations of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis (PC) from metastatic colorectal cancer (mCRC) in the United States are lacking.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev):

Title: Annals of surgical oncology

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1534-4681

ISSN (Print): 1068-9265

Publication date (Electronic): Apr 2019

Volume: 26

Issue: 4

Affiliations

[1 ] Harvard T. H. Chan School of Public Health, Boston, USA. trevor.hamilton@vch.ca.

[2 ] Department of Surgery, University of British Columbia, Vancouver, Canada. trevor.hamilton@vch.ca.

[3 ] Department of Surgery, University of British Columbia, Vancouver, Canada.

[4 ] Division of Medical Oncology, BC Cancer, Vancouver, Canada.

[5 ] Harvard T. H. Chan School of Public Health, Boston, USA.

[6 ] Erasmus Medical Center, Rotterdam, Netherlands.

Article

Publisher Item ID: 10.1245/s10434-018-07111-y

DOI: 10.1245/s10434-018-07111-y

PubMed ID: 30690682

SO-VID: 2856e11d-b565-4755-9cc6-c341ecd8c0a8

History

Data availability:

Comments

Comment on this article

scite_

Cited by 3

See all cited by